TokenPost·
Chemours Cuts High End of 2026 Adjusted EBITDA Forecast by $25 Million
The company now expects about 2% sales growth and reduced its 2026 capital-spending range to $220 million to $230 million.
More news
- TokenPostZalando’s Q3 GMV Rises 7.5% to €4.5 Billion as Revenue Grows 5.1%
- Crypto BriefingHyperliquid rise rattles crypto industry, draws White House attention
- TokenPostNasdaq-100 Futures Lead U.S. Stock Declines as Losses Narrow
- Crypto BriefingCoinbase restores crypto staking in New Jersey after state drops lawsuit
- The DefiantDemocrats Win Senate Control as CLARITY Act Remains Stalled
- TokenPostLindblad Raises 2026 Revenue Outlook to $870 Million to $885 Million